Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

oxaliplatin / Generic mfg.

NCT04687163: Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial

Recruiting

400

RoW

HAIC of 130 mg/m² Oxaliplatin, and 5-fu, HAIC of 85 mg/m² Oxaliplatin, and 5-fu, TKI

Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital

Hepatocellular Carcinoma

12/22

RESONANCE-II, NCT04483076: Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer

Recruiting

524

RoW

Chemotherapy drug, Gastrectomy, Laparoscopic exploration

Chinese PLA General Hospital

Gastric Cancer, Chemotherapy Effect

12/22

12/28

NCT03365765: mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Completed

RoW

Apatinib, YN968D1, Oxaliplatin, Eloxatin, 5-fluorouracil, Adrucil, Carac, Efudex, Efudix

Huashan Hospital

Apatinib

12/22

NCT04404491: Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence

Not yet recruiting

240

Procedural death 1, Camrelizumab, Capecitabine, Aibin, Radiotherapy, Radiation Therapy, Placebo

The First Affiliated Hospital of Henan University of Science and Technology

Esophageal Malignant Neoplasm, Local Recurrence

12/22

06/23

NCT02085655: PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Recruiting

264

RoW

pegaspargase, Oncaspar, Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Methotrexate, Dexamethasone, Thalidomide

Huiqiang Huang, Sun Yat-sen University

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

12/22

NCT03192644: The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Recruiting

162

RoW

TAI, TACE, epidoxorubicin and cisplatin and lipiodol, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

Sun Yat-sen University

Hepatocellular Carcinoma

12/22

12/24

NCT03192618: The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Recruiting

290

RoW

adjuvant transarterial chemoinfusion (TAI), mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

Sun Yat-sen University

Hepatocellular Carcinoma

12/22

12/24

GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Recruiting

294

RoW

Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1

Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd.

Gastric Cancer

12/22

03/23

NCT05362617: mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy

Recruiting

328

RoW

FOLFIRI

Second Affiliated Hospital, School of Medicine, Zhejiang University

Metastatic Colorectal Cancer

12/22

12/23

ZUMA-7, NCT03391466 / 2017-002261-22: Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

	Data from ZUMA-7 trial (Abstract #659) in 2L DLBCL at ASH 2022
	Dec 2022 - Dec 2022: Data from ZUMA-7 trial (Abstract #659) in 2L DLBCL at ASH 2022
	Data from ZUMA-7 trial (Abstract #259) in 2L DLBCL at ASH 2022
	Dec 2022 - Dec 2022: Data from ZUMA-7 trial (Abstract #259) in 2L DLBCL at ASH 2022
	Data from ZUMA-7 trial for 2L DLBCL at ASCO 2022
	Jun 2022 - Jun 2022: Data from ZUMA-7 trial for 2L DLBCL at ASCO 2022
	Approved for 2L DLBCL based on ZUMA-7 study
	Apr 2022 - Apr 2022: Approved for 2L DLBCL based on ZUMA-7 study
	Additional data from P3 ZUMA-7 trial for 2L DLBCL at ASH 2021
	Dec 2021 - Dec 2021: Additional data from P3 ZUMA-7 trial for 2L DLBCL at ASH 2021
	Data from ZUMA-7 trial for 2L DLBCL
	Jun 2021 - Jun 2021: Data from ZUMA-7 trial for 2L DLBCL
	Enrollment completion of P3 ZUMA-7 trial in 2L DLBCL
	Nov 2019 - Nov 2019: Enrollment completion of P3 ZUMA-7 trial in 2L DLBCL
More

Active, not recruiting

359

Europe, Canada, US, RoW

Axicabtagene Ciloleucel, KTE-C19, axi-cel, Yescarta ®, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders., Cyclophosphamide, Fludarabine

Kite, A Gilead Company

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

03/21

10/24

NCT04675983: A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Terminated

RoW

Sintilimab, Tyvyt, IBI308, Ramucirumab, LY3009806, IMC-1121B, Cyramza, Cisplatin, 5-fluorouracil, Oxaliplatin, Capecitabine

Innovent Biologics (Suzhou) Co. Ltd.

Gastric Adenocarcinoma

02/23

PRESERVE 1, NCT04607668 / 2019-003826-25: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

	Jan 2023 - Jun 2023: From PRESERVE1 trial for metastatic colorectal cancer
	Approved Clinical Trial Application in China for metastatic CRC
	Apr 2021 - Apr 2021: Approved Clinical Trial Application in China for metastatic CRC

Terminated

326

Europe, US, RoW

Trilaciclib, G1T28, CDK 4/6 inhibitor, Placebo

G1 Therapeutics, Inc.

Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity

02/23

03/23

RATIONALE 305, NCT03777657 / 2018-000312-24: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

	Jan 2023 - Dec 2023 : Submission in US for 1L gastric cancer
	Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma at ASCO-GI 2023
	Jan 2023 - Jan 2023: Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma at ASCO-GI 2023
	Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma
	Jan 2022 - Jan 2022: Data from RATIONALE 305 trial in combination with chemotherapy 1L treatment for G/GEJ adenocarcinoma

Active, not recruiting

997

Europe, Japan, US, RoW

Tislelizumab, BGB-A317, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-FU

BeiGene

Gastric, or Gastroesophageal Junction Adenocarcinoma

02/23

12/24

NCT03469479: Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria

Recruiting

252

RoW

FOLFOX, Hepatic Arterial Infusion Chemotherapy of FOLFOX, Hepatic resection

Sun Yat-sen University

Hepatocellular Carcinoma

03/23

ATTRACTION-5, NCT03006705: Study of Adjuvant ONO-4538 With Resected Gastric Cancer

	From ATTRACTION-5 trial for adjuvant gastric cancer and esophagogastric junction cancer
	Dec 2022 - Dec 2022: From ATTRACTION-5 trial for adjuvant gastric cancer and esophagogastric junction cancer

Completed

800

Japan, RoW

Nivolumab, BMS-936558, ONO-4538, MDX-1106, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Capecitabine, Placebo

Ono Pharmaceutical Co. Ltd, Bristol-Myers Squibb

Gastric Cancer

08/22

03/23

ESOPEC, NCT02509286 / 2015-001683-20: Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

Active, not recruiting

438

Europe

5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Carboplatin, Paclitaxel, Neoadjuvant radiation

University Hospital Schleswig-Holstein, Clinical Trials Unit Freiburg, University of Freiburg, University of Leipzig, University of Luebeck, University of Hamburg-Eppendorf

Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction

05/24

12/24

GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA

Active, not recruiting

507

Europe, RoW

Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid

Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group

OESOPHAGO-GASTRIC CARCINOMA

04/23

03/24

2022-002214-17: Repeat local treatment +/- neoadjuvant systemic therapy for recurrent colorectal liver metastases. Lokale behandeling +/- neoadjuvant systemische therapie voor recidieven van leveruitzaaiingen van dikke- en endeldarmkanker.

Ongoing

360

Europe

CAPOX (capecitabine with oxaliplatin) FOLFOX/FOLFIRI (5-fluorouracil/leucovorin with oxaliplatin or, Concentrate for solution for infusion, CAPOX (capecitabine with oxaliplatin) FOLFOX/FOLFIRI (5-fluorouracil/leucovorin with oxaliplatin or irinotecan) (with or without bevacizumab, per-patient based)

Amsterdam University Medical Centers, Amsterdam University Medical Centers

Recurrent colorectal liver metastases Recidief colorectale levermetastasen, Recurrent liver metastases from colorectal cancer Recidief lever uitzaaiingen van dikke- en endeldarmkanker, Diseases [C] - Cancer [C04]

NCT03398291: Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy

Recruiting

300

RoW

Synchronous resection of primary pancreatic cancer and liver oligometastasis, Standard chemotherapy

Fudan University

Pancreatic Cancer, Liver Metastases, Surgery

06/23

06/25

CIRCULATE, NCT04089631: Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation

Recruiting

4812

Europe

Capecitabine, Xeloda

Technische Universität Dresden

Colon Cancer Stage II

06/23

06/26

NCT06172205: Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Recruiting

192

RoW

intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect

07/26

07/27

GEMSTONE-303, NCT03802591: A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

	Jan 2023 - Jun 2023 : NDA filing in mainland China in 1L metastatic gastric adenocarcinoma/gastro-esophageal cancer
	Oct 2022 - Mar 2023 : Topline readout of the P3 trial in 1L metastatic gastric adenocarcinoma/gastro-esophageal junction adenocarcinoma

Completed

479

RoW

CS1001 monoclonal antibody, CS1001 placebo, Oxaliplatin, Capecitabine

CStone Pharmaceuticals

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

07/23

09/23

NCT05921942: The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer

Completed

RoW

Metformin

Ain Shams University

Colorectal Cancer

12/22

STELLAR, NCT02533271: Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer

Recruiting

600

RoW

Short-course radiotherapy with neoadjuvant chemotherapy, Long-term chemoradiotherapy

Chinese Academy of Medical Sciences

Cancer, Rectum

08/23

08/25

NCT03950154: Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer

Recruiting

198

RoW

Bevacizumab Injection [Avastin], Avastin, Oxaliplatin, Capecitabine, PD1-T cells, PD-1 monoclonal antibody-activated peripheral blood T-lymphocyte

Tianjin Medical University Cancer Institute and Hospital

Colorectal Cancer

08/23

NCT04342936: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting

RoW

Camrelizumab, SHR-1210, Investigator's choice of Chemotherapy

Jiangsu HengRui Medicine Co., Ltd.

Classical Hodgkin Lymphoma

08/23

12/23

NCT06134388: Sulfasalazine in Patients With Metastatic Colorectal Cancer

Recruiting

RoW

Sulfasalazine

Tanta University

Metastatic Colorectal Cancer

09/25

09/26

NCT03680261: Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy

Not yet recruiting

556

RoW

chemoradiotherapy, Study group (CRT), chemotherapy, Control group (CT)

Shanghai Zhongshan Hospital

Gastric Cancer

09/23

PEPCORLI, NCT02912052: Perioperative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis

Not yet recruiting

240

RoW

Peri-operative chemotherapy, XELOX, postoperative chemotherapy

The First Affiliated Hospital with Nanjing Medical University

Colon Cancer

10/23

NCT03780049: HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Recruiting

304

RoW

HAIC of FOLFOX, Hepatic artery infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin, H101, Recombinant Human Type-5 Adenovirus, Placebos, normal saline

Sun Yat-sen University

Hepatocellular Carcinoma

10/23

NCT04103398: TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma

Completed

162

RoW

TACE+sorafenib, TACE

Sun Yat-sen University

Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization

12/23

NCT05378867: A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC

Not yet recruiting

126

TRS003, China-approved Bevacizumab, mFOLFOX6

Zhejiang Teruisi Pharmaceutical Inc.

Metastatic Colorectal Cancer (CRC)

10/23

07/24

NCT03750669: Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Active, not recruiting

324

RoW

AG regimen, Nab-paclitaxel and Gemcitabine, mFolfirinox, Folic acid, 5- fluorouracil, irinotecan and oxaliplatin

Second Affiliated Hospital, School of Medicine, Zhejiang University

Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy

04/24

04/26

KONCLUDE, NCT02843191: Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy

Recruiting

358

RoW

Chemotherapy

Kyung Hee University Hospital at Gangdong, Korean Society of ColoProctology

Rectal Cancer

11/23

07/24

NCT05624138: The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy

Recruiting

RoW

Placebo tablets, Oxaliplatin, Fluorouracil, calcium leucovorin, Ketotifen Oral Tablet, ketotifen

Tanta University

Neuropathy;Peripheral

11/23

11/24

BRAZIL-TNT, NCT05081687: Brazilian Total Neoadjuvant Therapy Trial

Recruiting

150

RoW

Folfirinox, mFOLFIRINOX, FOLFOXIRI, 5-FU, oxaliplatin, irinotecan

Hospital Israelita Albert Einstein, Ministry of Health, Brazil

Colorectal Neoplasms

11/23

12/23

NCT01815853: Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer

Recruiting

620

RoW

Neoadjuvant Chemoradiotherapy, Neoadjuvant Chemotherapy, R0 D2 Gastrectomy, Adjuvant Chemotherapy

Sun Yat-sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Anhui Medical University, Liaoning Cancer Hospital & Institute, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangxi Medical University Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Zhejiang Cancer Hospital, First Hospital of China Medical University, First People's Hospital of Hangzhou

Gastric Cancer

12/23

12/25

PREACT, NCT03013010: Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy

Recruiting

682

RoW

Tegafur-Gimeracil-Oteracil Potassium, S-1, Chemoradiotherapy, radiochemotherapy, Gastric resection, Gastrectomy, Oxaliplatin

Shanghai Cancer Hospital, China, Fudan University, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Huadong Hospital

Stomach Neoplasm, GastroEsophageal Cancer, Adenocarcinoma, Locally Advanced Cancer, Chemoradiation

12/23

CISPD-4, NCT03983057: Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Recruiting

830

RoW

Anti-PD-1 monoclonal antibody

Zhejiang University

Pancreatic Cancer

12/23

12/24

DIRECT, NCT03899636: A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

Recruiting

528

Modified FOLFIRINOX Regimen, NanoKnife System

Angiodynamics, Inc.

Stage III Pancreatic Cancer

12/23

NCT05680870: The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients

Not yet recruiting

Omeprazole, Omez

Aya Mohamed Sadek Elsaid

Chemotherapy Induced Peripheral Neuropathy

12/23

KEYNOTE 811, NCT03615326 / 2018-000224-34: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

	From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021
	Jun 2021 - Jun 2021: From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021

Active, not recruiting

738

Europe, Japan, US, RoW

Pembrolizumab, Keytruda®, MK-3475, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab, Herceptin®

Merck Sharp & Dohme LLC

Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma

03/24

12/24

NCT06177041: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Recruiting

486

RoW

M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine

FutureGen Biopharmaceutical (Beijing) Co., Ltd

Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

01/27

04/27

NCT06201065: FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Recruiting

200

RoW

Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab, oxaliplatin , fluorouracil, and leucovorin

Sun Yat-sen University

Hepatocellular Carcinoma

07/25

12/26

COLAGE, NCT03828227: QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.

Active, not recruiting

Europe

OPTIMOX-bevacizumab, Folinic acid (FA)-5-fluorouracil (5-FU)-oxaliplatin [OPTIMOX], Avastin, Capecitabine plus bevacizumab, capecitabine

GERCOR - Multidisciplinary Oncology Cooperative Group

Elderly Patients, Metastatic Colorectal Cancer, Quality of Life

11/23

09/24

NCT00217737: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Active, not recruiting

3610

Canada, US, RoW

Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669

National Cancer Institute (NCI)

Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Lynch Syndrome, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7

09/24

LAPIS, NCT03941093 / 2019-001925-28: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer

Active, not recruiting

284

Europe, Canada, US, RoW

Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, FG-3019, Gemzar, Abraxane, Eloxitan, Leucovorin, Camptosar, 5-Fluracil, Efudex, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

FibroGen

Pancreatic Cancer Non-resectable

04/24

NCT04416854: The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

Recruiting

627

RoW

resection of primary tumor, XELOX, mFOLFOX6

Fudan University

Metastatic Colon Cancer, Surgery

12/23

12/25

EA2183, NCT04248452: Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Recruiting

314

Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, Irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8

03/28

NCT04358354: Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer

Recruiting

388

RoW

Irinotecan, CPT-11, Oxaliplatin, LOHP, 5-fluorouracil, 5-FU

Sixth Affiliated Hospital, Sun Yat-sen University

Metastatic Gastric Cancer

12/23

12/24

NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Recruiting

386

RoW

mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab

Fudan University

Colorectal Cancer, Liver Metastases

12/23

12/26

SOLARIS, NCT04094688: Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruiting

455

Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Colorectal Adenocarcinoma

01/25

07/25

LIQUIPANC, NCT06391892: Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Recruiting

100

Europe

Neoadjuvant chemotherapy instead of upfront surgery, Experimental, Upfront surgery, Standard of care

Elisabethinen Hospital, Medical University Innsbruck

Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model

12/25

12/26

COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Active, not recruiting

610

RoW

AK104, Oxaliplatin, Capecitabine, Placebo

Akeso

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

08/24

04/25

CRC01, NCT06226857: Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Recruiting

355

RoW

Cetuximab, panitumumab

City Clinical Oncology Hospital No 1, Atlas Biomed, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka

Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation

12/26

12/27

NCT06206733: ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Recruiting

780

RoW

ASKB589, Oxaliplatin, Capecitabine, Tislelizumab, Placebo

AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

12/26

12/28

KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Recruiting

480

RoW

KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator

3D Medicines (Sichuan) Co., Ltd.

Biliary Tract Neoplasms

07/24

NeoCol, NCT01918527 / 2013-002363-26: Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer

Active, not recruiting

250

Europe

Capecitabine, Oxaliplatin

Vejle Hospital

Colon Cancer

06/23

02/25

ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting

774

Europe

LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine

Federation Francophone de Cancerologie Digestive

Colonic Adenocarcinoma

02/24

08/25

HR070803-307, NCT06217042: HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting

524

RoW

HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, gemcitabine; capecitabine

Fudan University

Pancreatic Cancer

03/27

07/28

NCT05231382: Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma

Recruiting

426

RoW

Raltitrexed, oxaliplatin (SALOX) treatment, Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment

Sun Yat-sen University

Hepatocellular Carcinoma

02/24

02/25

KEYNOTE-585, NCT03221426 / 2016-004408-76: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/)

Jan 2024 - Dec 2024: From P3 KEYNOTE-585 trial for patients with gastric and gastroesophageal junction adenocarcinoma

Active, not recruiting

1007

Europe, Canada, Japan, US, RoW

Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®

Merck Sharp & Dohme LLC

Gastric Cancer, Gastroesophageal Junction Cancer

02/24

06/25

KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Active, not recruiting

115

RoW

Merck Sharp & Dohme LLC

Gastric Cancer, Gastroesophageal Junction Cancer

02/24

06/25

PelvEx II, NCT04389086: Induction Chemotherapy for Locally Recurrent Rectal Cancer

Recruiting

364

Europe

Combination drug, CAPOX, FOLFOX, FOLFIRI, Chemoradiotherapy, Surgery locally recurrent rectal cancer

Catharina Ziekenhuis Eindhoven

Recurrent Rectal Cancer

03/24

03/30

SHR-A1811-309, NCT06199973: Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Recruiting

120

RoW

SHR-A1811, TAS-102, Regorafenib , Fruquintinib

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Colorectal Cancer

04/26

06/26

NCT03362177 / 2017-002992-25: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Active, not recruiting

162

Europe, Canada, US, RoW

Romiplostim, Placebo

Amgen

Chemotherapy-induced Thrombocytopenia

01/24

01/25

BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Recruiting

308

RoW

mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab

Fudan University

Colorectal Carcinoma, Liver Metastases

03/24

03/26

PARADIGM biomarker, NCT02394834: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Active, not recruiting

757

Japan

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab

Takeda

Colorectal Cancer

03/25

NCT04835064: Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Not yet recruiting

600

Nab paclitaxel, Abraxane, Gemcitabine, Gemzar, mFOLFIRINOX, modified FOLFIRINOX regimen

Fudan University

Pancreatic Adenocarcinoma

04/24

12/24

NCT02912559: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Active, not recruiting

700

Europe, US

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment

National Cancer Institute (NCI)

Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8

04/25

NCT04370925: Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis

Recruiting

688

RoW

Radical colectomy, HIPEC, Systemic chemotherapy

Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University

Colorectal Cancer

04/24

04/26

KRYSTAL-10, NCT04793958 / 2020-004048-27: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Active, not recruiting

461

Europe, Canada, US, RoW

MRTX849, Cetuximab, Erbitux, mFOLFOX6 Regimen, FOLFIRI Regimen

Mirati Therapeutics Inc.

Advanced Colorectal Cancer, Metastatic Colorectal Cancer

02/25

02/26

CIME, NCT06346197: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Not yet recruiting

124

Europe

Balstilimab, Botensilimab, Folfox Protocol, XELOX, Nivolumab

Centre Leon Berard, Agenus Inc.

Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer

05/28

ChiCTR2000032992: A Phase III Randomized Controlled Trial of Comparison of Survival Benefit of Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed With Sorafenib for Patients With intermediate- and advanced-stage Hepatocellular Carcinoma

Not yet recruiting

130

Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed ;Oral sorafenib

Fujian Cancer Hospital; Fujian Cancer Hospital, Hospital funding

Hepatocellular carcinoma

ChanghaiH-PP09, NCT04931381: Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer

Recruiting

100

RoW

Chemotherapy guided by organoid drug sensitivity test

Changhai Hospital

Advanced Pancreatic Cancer

05/24

05/25

ChanghaiH-PP08, NCT04931394: Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer

Recruiting

200

RoW

Adjuvant chemotherapy guided by organoid drug sensitivity test

Changhai Hospital

Pancreatic Cancer

05/24

05/25

IROCAS, NCT02967289 / 2016-001491-29: IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

Active, not recruiting

792

Europe, Canada

Irinotecan, Campto, Folfox Protocol, acid folinic + oxaliplatine + 5-FU

UNICANCER, Canadian Cancer Trials Group, GONO GROUP

Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)

06/24

06/27

TRIBE-C, NCT04230187: Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer

Recruiting

528

RoW

mFOLFOXIRI plus Bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, mFOLFOX6 Plus Bevacizumab

Yanhong Deng

Colorectal Cancer

06/24

06/26

NCT04351867: A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer

Not yet recruiting

196

RoW

docetaxel plus oxaliplatin and capecitabine, Three medicine combined, oxaliplatin plus capecitabine, Two medicine combined

LiNing

Stomach Neoplasms

06/24

RCNAC, NCT05201430: Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

Recruiting

300

RoW

FOLFOXIRI, 5-Fu, Oxaliplatin, Irinotecan, Surgery, CapeOX, Capecitabine

Fudan University

Rectal Cancer

06/24

07/27

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

12/24

07/25

NCT06411171: Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Not yet recruiting

Pembrolizumab plus chemotherapy (FLOT), docetaxel, oxaliplatin, fluorouracil, and leucovorin (the FLOT regimen)

xiaohua li

Gastroesophageal Junction Cancer

09/25

09/28

DOSAGE, NCT06275958: Study: Upfront Dose-Reduced Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Not yet recruiting

587

Europe

Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%), Monotherapy, Dose-reduced (75%)

Leiden University Medical Center, Dutch Colorectal Cancer Group, Stichting Darmkanker

Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy

06/28

12/28

FOxTROT2France, NCT06293625: Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced But Resecable Colon Cancer in the Elderly of 70 Years Old or More

Recruiting

150

Europe

Folfox, Surgery

Centre Hospitalier Universitaire Dijon

Colon Cancer

06/32

CR-SEQUENCE, NCT03635021 / 2018-000347-60: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Active, not recruiting

419

Europe

FOLFOX regimen, Panitumumab, Bevacizumab, FOLFIRI regimen

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen

Colorectal Cancer

06/25

NCT05074966: The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Recruiting

314

RoW

Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab

Chinese Academy of Medical Sciences

Colo-rectal Cancer

06/24

06/25

GRECCAR 15, NCT03879109: Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer

Active, not recruiting

Europe

Chemotherapy FOLFIRINOX, 6 cycles, Radiochemotherapy, Surgery

University Hospital, Bordeaux

Rectal Cancer

07/24

12/27

NCT03975049: Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Not yet recruiting

933

Chemoradiation, FOLFOXIRI Protocol, Folfox Protocol

Sixth Affiliated Hospital, Sun Yat-sen University

Rectal Cancer, Chemotherapy Effect

07/24

07/29

NEO-RT, NCT06205485: Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Not yet recruiting

250

Leucovorin, Oxaliplatin, Fluoruracil, Capecitabine, Radiation

Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, SWOG Cancer Research Network

Rectal Cancer

01/30

06/30

NCT02102789: A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis

Recruiting

142

RoW

mFOLFOX6, Oxaliplatin, Leucovorin, 5-fluorouracil, HAI, floxuridine (FUDR), dexamethasone

Yuhong Li

Metastatic Colorectal Cancer

08/24

12/24

RuCorT-01, NCT04103697: Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer

Enrolling by invitation

560

RoW

Capecitabine, Xeloda, Oxaliplatin, Radiotherapy, Rectal cancer surgery

Blokhin's Russian Cancer Research Center

Rectal Neoplasms Malignant, Rectum Carcinoma, Rectal Cancer

08/24

NCT03961841: Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma

Not yet recruiting

900

chemoradiation with weekly 5Fu and oxaliplatin, Perioperative mFLOT, Perioperative FOLFOX

Sixth Affiliated Hospital, Sun Yat-sen University

Esophagogastric Junction Disorder, Neoplasms

08/24

08/29

ChiCTR2100048255: A randomized, open-label phase III clinical study on the efficacy and safety of oxaliplatin combined with capecitabine versus docetaxel combined with Seggio in the treatment of stage IIIc gastric cancer with postoperative adjuvant chemotherapy

Not yet recruiting

oxaliplatin plus capecitabine ;docetaxel plus S-1

Anhui Provincial Tumor Hospital; Anhui Provincial Tumor Hospital, self-raised

gastric cancer

NCT06017583: Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

Recruiting

RoW

Tislelizumab, Capecitabine, Oxaliplatin, SIB-IMRT, IMRT

Yong Zhang,MD

Rectal Neoplasms

08/24

08/26

NCT04617821: AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Recruiting

300

RoW

Nab paclitaxel plus gemcitabine, AG regimen, mFOLFIRINOX, modified FOLFIRINOX regimen

Fudan University

Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma

09/24

COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting

202

Europe, US, RoW

177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)

ITM Solucin GmbH

Neuroendocrine Tumors

06/27

09/27

PROMENADE, NCT02974556: Proactive Management of Endoperitoneal Spread in Colonic Cancer

Not yet recruiting

140

Europe

Standard surgical treatment, Proactive management, Standard adjuvant systemic chemotherapy, adjuvant capecitabine and oxaliplatin (CAPOX), adjuvant 5-FU and oxaliplatin (FOLFOX)

University of Roma La Sapienza

Colon Cancer, Intraperitoneal Rectal Cancer

09/24

09/25

POLARGO, NCT04182204 / 2018-003727-10: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting

270

Europe, Canada, US, RoW

Polatuzumab Vedotin, Rituximab, Mabthera; Rituxan, Gemcitabine, Oxaliplatin

Hoffmann-La Roche

Diffuse Large B-Cell Lymphoma

09/24

03/25

ECTX, NCT01460589: Early Commencement of Adjuvant Chemotherapy for Colon Cancer

Active, not recruiting

440

RoW

timing to initiate the adjuvant chemotherapy, early commencement of chemotherapy

Kyungpook National University Hospital

Colon Cancer

10/24

12/24

RuCorT-02, NCT04134897: Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer

Enrolling by invitation

316

RoW

Capecitabine, Xeloda, Oxaliplatin, Radiotherapy, Rectal cancer surgery

Blokhin's Russian Cancer Research Center

Rectal Neoplasms Malignant, Rectum Carcinoma, Rectal Cancer

10/24



	Diseases Companies Products Productz Mechanisms of Action Sites